Reckitt Benckiser appoints regulatory affairs director

LoGalbo joins RB from Pfizer Consumer Health; RB also announces merger agreement with Schiff Nutrition Intl.

Reckitt Benckiser recently announced the appointment of Suzanne LoGalbo to the position of Regulatory Affairs Director, Reckitt Benckiser North America. LoGalbo joins RB from Pfizer Consumer Health.

While at Pfizer, LoGalbo most recently held the position of Global Regulatory Portfolio Lead Worldwide Regulatory Strategy. Prior to Pfizer, she was the head of Global Regulatory Affairs North America for Novartis Consumer Health. She has also held regulatory leadership roles at Polaris, Solvay, Arganon, and Sandoz.

LoGalbo brings with her global and North American leadership experience in the regulatory environment including Rx-to-OTC switches, compliance, government relations, and global NPD rollouts within the consumer health space. At RB, the U.S. and Canadian regulator teams will now report to LoGalbo.

LoGalbo holds a Juris Doctor from Rutgers University School of Law and holds a BS in pharmaceutical studies.

Reckitt Benckiser is a global consumer goods leader in health, hygiene, and home. With a purpose of delivering innovative solutions for healthier lives and happier homes, RB’s portfolio is led by 19 global Powerbrands including in the OTC health category Mucinex, Durex, Nurofen, Strepsils Gaviscon, and Scholl, and in the hygiene category Lysol, Dettol, Clearasil, Veet, Harpic, Bang, Mortein, and Finish.

The company recently announced that Reckitt Benckiser Group PLC signed a definitive merger agreement with Schiff Nutrition International, Inc., a provider of branded vitamins, nutrition supplements, and nutrition bars in the U.S. and elsewhere.
 

Companies in this article
More in Home